Navigation Links
Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants

FRISCO, Texas, Aug. 31, 2011 /PRNewswire/ -- Assured Pharmacy, Inc. (Pink Sheets: APHY, the "Company"), a growing chain of specialty pharmacies that provide advanced prescription services to a diverse array of medical professionals and their patients, announced today that it sold in a private placement to an accredited investor a 16.0% (per annum) senior convertible debenture for an aggregate principal amount of $400,000 due December 1, 2012.  The debenture is convertible into 317,460 shares of the Company's common stock at an initial conversion price of $1.26 per share, subject to adjustment.  As part of the private placement, the investor received a warrant to purchase an aggregate of 380,952 shares of the Company's common stock.  The warrant is exercisable for a period of three years from the date of issuance at an initial exercise price of $1.51 per share, subject to adjustment.  The investor may exercise the warrant on a cashless basis if the shares of common stock underlying the warrant have not been registered pursuant to an effective registration statement at the time of exercise.  The funds received from the investor will be directed to the continued development of the Company's business plan and general working capital purposes.  

This financing is supporting the Company's ongoing business expansion and investment into solidifying its supply chain of prescription medications.  "We are very pleased to have the support of this investment as we enter the next phase of our business model," stated Mr. Robert DelVecchio, Chief Executive Officer of Assured Pharmacy.  "As we lay the foundation for expanding our pharmacy footprint into new markets, improving our financial position with suppliers is critical and this financing furthers that requirement."

The securities sold by the Company in the private placement were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were sold in reliance upon exemptions from the registration requirements of the Securities Act pursuant to Regulation D promulgated under the Securities Act. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.

The foregoing information is a summary of the transaction described above, is not complete, and is qualified in its entirety by reference to a more detailed description of the financing and the full text of the agreements, each of which will be available on the OTC Markets website and are available at under our ticker symbol, APHY.PK. Readers should review the detailed description of the offering along with the agreements for a complete understanding of the terms and conditions associated with this financing transaction.

About Assured Pharmacy, Inc.

Assured Pharmacy, Inc. is engaged in the business of providing specialty pharmacy services to patients and physicians in the treatment of chronic pain. The Company derives its revenue primarily from the sale of highly regulated prescription pain medications and does not keep in inventory non-prescription drugs or health and beauty related products inventoried at traditional pharmacies. The majority of the Company's business is derived from repeat business from its customers. "Walk-in" prescriptions from physicians are limited. The Company currently has four operating pharmacies.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Erika Moran/Adam Holdsworth
The Investor Relations Group
11 Stone St. 3rd Floor
New York, NY

SOURCE Assured Pharmacy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location
2. Assured Pharmacy Upgrades to OTC Pink Current Information
3. Assured Pharmacy Engages The Investor Relations Group
4. Assured Pharmacy, Inc. Receives Gross Proceeds of $200,000 from Sale of Convertible Debentures and Warrants
5. Assured Pharmacy Completes Audit of 2010 Financial Statements
6. Assured Pharmacy Announces Reverse Stock Split
7. Assured Pharmacy Reports Same Store Sales for the Month of January 2011
8. Assured Pharmacy Completes Audit of 2008-2009 Financial Statements
9. Assured Pharmacy Reports Same Store Sales for the Month of December 2010
10. Assured Pharmacy, Inc. Receives Gross Proceeds of $300,000 from Sale of Convertible Debentures and Warrants
11. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
Post Your Comments:
(Date:11/27/2015)... 2015 Research and Markets ( ) ... Devices Market 2015-2019" report to their offering. ... this report, the author the present scenario and growth ... To calculate the market size, the report considers revenue ... Hormonal IUDs and copper IUDs. The report forecasts the ...
(Date:11/26/2015)... November 27, 2015 ... --> Medical alert ... system (PERS) market is expected ... years with APAC being the ... see a high CAGR between ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
Breaking Medicine Technology:
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Avid collector, ... Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most famous ... Canterbury House at the University of Michigan in Ann Arbor. The According to Hawley, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
Breaking Medicine News(10 mins):